Advertisement

Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x100px
Collaboration › Details

Bit Bio–Synthego: gene editing, 202308– collab expansion applying gene editing to otpi-ox technology to engineer human cells for cell therapies

 

Period Period 2023-08-24
Organisations Partner, 1st Bit Bio Ltd. (bit.bio)
  Partner, 2nd Synthego Corporation
Products Product genome editing (gene editing)
  Product 2 opti-ox™ cell reprogramming platform (optimised, inducible over-expression)
     

Synthego Corporation. (8/24/23). "Press Release: Synthego and bit.bio Expand Strategic Partnership to Build a Platform for the Development of Safer and More Efficient Genetic Engineering of Human Cells for Cell Therapies". Redwood City, CA & Cambridge.

> Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies

> bit.bio aims to leverage technology to increase efficiency of human cell engineering and accelerate the development of highly scalable cell therapies that are capable of treating millions of patients.


Synthego, a leading provider of industrialized genome editing solutions that accelerate discovery to clinic journey, and bit.bio, the company coding human cells for novel cures, today announced a strategic partnership to build a platform centered on the implementation of synthetic circuitry in cells for therapeutic application.

bit.bio is building a pipeline of cell therapies focused on areas of unmet clinical need. The partnership will apply Synthego’s expertise in gene editing to bit.bio’s opti-ox™ precision cell programming technology, with the aim of discovering and developing advanced genetic engineering solutions for cell therapies.

Synthego will rapidly design, build, test and deliver an end-to-end optimized multiplexed genetic editing strategy. The implementation of the multiplexed opti-ox engineering approach will reduce the number of engineering steps required, with the potential of shortening clinical cell engineering and development timelines by up to 10 months.

"bit.bio is the leading synthetic biology company focussed on human cells. We are thrilled to deepen our partnership with bit.bio to facilitate a leap forward in the development of synthetic biology-based cell therapies," said Paul Dabrowski, CEO at Synthego. “By coordinating our respective technologies, expertise and resources, we will unlock new opportunities for addressing critical challenges in the field by advancing the R&D cycle of innovative cell therapies.”

"Synthego are experts when it comes to industrialized cell engineering," stated Mark Kotter, CEO at bit.bio. "Teaming up with Synthego will boost our genetic engineering capabilities. We expect efficiency gains across bit.bio’s platform which will allow us and our partners to deliver transformative therapies more rapidly to patients in need."


About Synthego

Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms and products for science at scale. With its foundations in engineering disciplines, the company’s platform technologies vertically integrate proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance basic research, target validation, and clinical trials. With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation, enabling the next generation of medicines by delivering genome editing at an unprecedented scale.

Media Contact

Avi Raval
Chief Business Officer
pr@synthego.com


About bit.bio

bit.bio is a synthetic biology company focused on human cells that is advancing medicine (UN SDG9) and enabling curative treatments (UN SDG3). The company does this by industrializing the manufacture of human cells and making them more accessible. The company was spun out of the University of Cambridge in 2016 and has since raised approximately $200m from investors such as Arch Ventures, Foresite Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, Verition Fund and Puhua Capital.

bit.bio’s opti-ox™ precision cell programming and manufacturing technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step. This can be achieved within days and at industrial scale, while maintaining exceptional purity and unparalleled consistency.

Our discovery platform extends this approach to any desired cell type by identifying the transcription factor combinations that define cell states (including identity, cell subtype identity, maturity) using high throughput screens and advanced data analysis. We believe that opti-ox can revolutionize regenerative medicine similarly to how CRISPR is unlocking gene therapy.

bit.bio's cell therapy pipeline is focused on serious diseases that currently lack effective treatments. Our preclinical research areas include liver, immunology and metabolic disease, and we have a collaboration with BlueRock Therapeutics (Bayer AG) to create therapeutics for autoimmune and inflammatory disorders. In addition, our extensive ioCells™ research cell product portfolio, which includes wild type and disease model cells, is opening up new possibilities for studying human biology and developing new medicines in both research and high throughput and high content drug discovery.

For more information, please visit www.bit.bio

Contact

Media
Sofia Goulart
bitbio@aprilsix.com
+44 7554 014857

Investors
Mike Booth, SVP External Affairs
ir@bit.bio
+44 1223 787297

   
Record changed: 2023-09-09

Advertisement

Picture Demy-Colton BioFuture 2024 NYC 3 Healthcare Revolution 650x200px

More documents for Bit Bio Ltd. (bit.bio)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px




» top